STRM vs. BIVI, NRBO, NRXS, APTO, AXDX, KALA, AIM, SYBX, EVAX, and TCRT
Should you be buying Streamline Health Solutions stock or one of its competitors? The main competitors of Streamline Health Solutions include BioVie (BIVI), NeuroBo Pharmaceuticals (NRBO), NeurAxis (NRXS), Aptose Biosciences (APTO), Accelerate Diagnostics (AXDX), KALA BIO (KALA), AIM ImmunoTech (AIM), Synlogic (SYBX), Evaxion Biotech A/S (EVAX), and Alaunos Therapeutics (TCRT). These companies are all part of the "medical" sector.
BioVie (NASDAQ:BIVI) and Streamline Health Solutions (NASDAQ:STRM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends.
BioVie has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Streamline Health Solutions has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.
Streamline Health Solutions received 208 more outperform votes than BioVie when rated by MarketBeat users. However, 64.00% of users gave BioVie an outperform vote while only 51.61% of users gave Streamline Health Solutions an outperform vote.
4.6% of BioVie shares are owned by institutional investors. Comparatively, 31.7% of Streamline Health Solutions shares are owned by institutional investors. 4.8% of BioVie shares are owned by insiders. Comparatively, 26.7% of Streamline Health Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Streamline Health Solutions has higher revenue and earnings than BioVie. Streamline Health Solutions is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.
BioVie has a net margin of 0.00% compared to BioVie's net margin of -82.75%. BioVie's return on equity of -30.84% beat Streamline Health Solutions' return on equity.
BioVie presently has a consensus price target of $8.00, suggesting a potential upside of 1,526.68%. Streamline Health Solutions has a consensus price target of $2.00, suggesting a potential upside of 532.91%. Given Streamline Health Solutions' higher probable upside, research analysts plainly believe BioVie is more favorable than Streamline Health Solutions.
In the previous week, BioVie had 2 more articles in the media than Streamline Health Solutions. MarketBeat recorded 3 mentions for BioVie and 1 mentions for Streamline Health Solutions. BioVie's average media sentiment score of 0.44 beat Streamline Health Solutions' score of 0.31 indicating that Streamline Health Solutions is being referred to more favorably in the news media.
Summary
Streamline Health Solutions beats BioVie on 10 of the 16 factors compared between the two stocks.
Get Streamline Health Solutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for STRM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Streamline Health Solutions Competitors List
Related Companies and Tools
